Litcius/Paper detail

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Chao Shan, Ying Chen, Meiqin Liu, Bei Li, Xu-Rui Shen, Qi Wang, Yan Zhu, Ren-Di Jiang, Lei Zhang, Qian Li, Huanjun Zhang, Yiwu Zhou, Ralph S. Baric, Xi Wang, Hao-Rui Si, Wei Zhang, Juan Min, Xing‐Lou Yang, Zheng‐Li Shi, Peng Zhou

2020UNC Libraries23 citationsDOIOpen Access PDF

Abstract

COVID-19 has spread worldwide since 2019 and is now a severe threat to public health. We previously identified the causative agent as a novel SARS-related coronavirus (SARS-CoV-2) that uses human angiotensinconverting enzyme 2 (hACE2) as the entry receptor. Here, we successfully developed a SARS-CoV-2 hACE2 transgenic mouse (HFH4-hACE2 in C3B6 mice) infection model. The infected mice generated typical interstitial pneumonia and pathology that were similar to those of COVID-19 patients. Viral quantification revealed the lungs as the major site of infection, although viral RNA could also be found in the eye, heart, and brain in some mice. Virus identical to SARS-CoV-2 in full-genome sequences was isolated from the infected lung and brain tissues. Last, we showed that pre-exposure to SARS-CoV-2 could protect mice from severe pneumonia. Our results show that the hACE2 mouse would be a valuable tool for testing potential vaccines and therapeutics.

Topics & Concepts

Angiotensin-converting enzyme 2PathogenesisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)Genetically modified mouse2019-20 coronavirus outbreakTransgeneBiologyMedicineGeneImmunologyGeneticsInternal medicineDiseaseInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 | Litcius